Navigation Links
Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX

Affymetrix Inc. (Nasdaq: AFFX), announced today the launch of the new GeneChip(R) Globin-Reduction kits and associated protocol developed in conjunction with PreAnalytiX -- a joint venture between QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) and BD (Becton, Dickinson and Company). The new kits optimize the PreAnalytiX PAXgene(TM) Blood RNA System for use with Affymetrix GeneChip technology and improve gene expression profile results of cellular RNA extracted from whole blood.

The combination of the GeneChip Blood RNA Concentration Kit (featuring the PAXgene Blood RNA System) and the GeneChip Globin-Reduction RNA Controls standardizes all the steps of whole blood RNA processing -- from sample stabilization to analysis on GeneChip microarrays. This has been a major challenge in expression studies of whole blood, as prior RNA preparation methods have often yielded expression results with variable levels of sensitivity.

Use of the Globin-Reduction Protocol and associated reagent kits enables researchers to detect subtle changes in gene expression by reducing the overwhelming amounts of globin messenger RNA (mRNA) present in whole blood. Large amounts of globin mRNA can significantly interfere with gene expression assay results. High globin mRNA levels contributed from a fraction of the red blood cells have typically masked the less abundant, but more important, changes of gene expression associated with white blood cells, such as lymphocytes and monocytes. Counteracting the effects of globin mRNA during target preparation significantly increases assay sensitivity on GeneChip arrays.

The GeneChip Globin Reduction Protocol links PreAnalytiX' already proven standard for whole blood collection, stabilization and isolation of RNA with Affymetrix' leading product line for microarray-based analysis of whole blood cellular RNA profiles.

"An accurate picture of in vivo gene expression profiles is essential for understanding gene regul ation as it relates to different disease states and a patient's response to drug therapy," said Noel Doheny, Vice President of PreAnalytiX and QIAGEN. "We continue to see a strong market trend towards the correlation of gene expression profiles of whole blood and tissue samples. With the new GeneChip Globin-Reduction Protocol and associated reagent kits, standardization of the entire pre-analytical and analytical process for whole blood gene expression profiling can now be accomplished."

"The ability of the PAXgene(TM) Blood RNA system to preserve RNA expression levels from the time of sample collection to the time of RNA isolation is a critical component to obtaining accurate gene expression profiles," said Lianne McLean, Sr. Director, Gene Expression Marketing, Affymetrix. "The optimized protocol, the PAXgene system and the controls will significantly improve the ability to obtain high quality profiles from blood, thus enabling clinical research and collecting samples for multi-site clinical trials."

About PreAnalytiX GmbH:

The purpose of PreAnalytiX GmbH, a Swiss-based joint venture between BD (Becton, Dickinson and Company) and QIAGEN N.V., is to develop, manufacture, and market integrated systems for the collection, stabilization, and purification of nucleic acids (DNA and RNA) for molecular diagnostic testing. The first product from PreAnalytiX, the PAXgene(TM) Blood RNA System, was launched in April 2001, and has set a new standard for stabilizing whole blood cellular RNA profiles at the time of blood collection in an evacuated blood collection tube. This enables researchers and clinicians to perform more accurate analysis of gene expression profiles without the variations caused by sample collection, storage, transport or fractionation while relying on highly standardized and proven sample collection principles. Additional information on PreAnalytiX can be found under http://www.preanalytix.com .

About Affymetrix:

Affy metrix scientists invented the world's first microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,200 systems have been shipped around the world and over 3,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyze the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company maintains important sales and marketing operations in Europe and Asia and has about 900 employees worldwide.


'"/>

Source:Affymetrix


Related biology news :

1. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
2. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
3. Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance
4. Affymetrix and Stratagene Announce Strategic Software Alliance
5. Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences
6. Affymetrix and bioMerieux Extend Their Agreement on GeneChip(R) Technology to Breast Cancer Diagnostics
7. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping
8. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
9. Affymetrix 500K array used to identify memory gene
10. Kinovate Life Sciences Launches Nittophase?High Performance Solid Support For Oligonucleatide Synthesis
11. IMF Launches World’s First DNA Database for Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/12/2020)... ... August 12, 2020 , ... Mosio recently announced its newly ... health agencies of all sizes. With a focus on tracking symptoms and monitoring ... health care, Mosio helps public health departments automate communications and provide more personalized ...
(Date:7/31/2020)... ... July 30, 2020 , ... BioFactura, ... contract awarded by the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) ... develop, optimize, and scale-up a highly efficient mammalian cell culture-based bioprocess suitable to ...
(Date:7/10/2020)... ... July 08, 2020 , ... Overcoming Comparability ... Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, ... is the most effective way to complete one? Will the study comply with ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... and SOMERSET, N.J (PRWEB) , ... July 29, ... ... genome editing company, and Catalent, the leading global provider of advanced delivery technologies, ... health products, today announced that they have entered into a strategic partnership whereby ...
(Date:7/22/2020)... ... ... Join experts from Reed Tech , Gary Saner, Sr. Manager, Information Solutions Life ... webinar on Thursday, August 13, 2020 at 11am EDT (4pm BST/UK). , The ... medical devices, the NMPA has departments dealing with medical device registration (pre-market approvals) and ...
(Date:7/18/2020)... , ... July 17, 2020 , ... ... consulting firm for the life sciences and food industries, is pleased to announce ... of Clinical Research – Business Development. , Charles is an accomplished and results-driven ...
(Date:7/10/2020)... LEXINGTON, Mass. (PRWEB) , ... July 09, 2020 ... ... novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, ... executive team and oversee the clinical development of Sentien’s lead product, SBI-101. ...
Breaking Biology Technology: